{"filing":{"accession_number":"0001193125-26-336886","cik":"0001991792","ticker":"CGON","company_name":"CG Oncology, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"ck0001991792-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1991792/000119312526336886/ck0001991792-20260806.htm"},"events":[{"id":25570,"run_id":23209,"accession_number":"0001193125-26-336886","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"CG Oncology issued a press release on August 6, 2026 announcing second quarter 2026 financial results, including net loss of $79.1 million, R\u0026D expenses of $54.7 million, and cash position of $1.0 billion.","company_name":"CG Oncology, Inc.","ticker":"CGON","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26443,"accession_number":"0001193125-26-336886","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"CG Oncology issued a press release on August 6, 2026 announcing financial results for the quarter ended June 30, 2026, including condensed consolidated statements of operations and balance sheet data. The filing explicitly states \"CG Oncology Reports Second Quarter 2026 Financial Results\" and discloses key metrics such as net loss of $79.1 million (vs. $41.4 million prior year), R\u0026D expenses of $54.7 million, and cash position of $1.0 billion. This is a standard quarterly earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:56:15.688702+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":25571,"run_id":23209,"accession_number":"0001193125-26-336886","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"CG Oncology filed Amendment No. 2 to its prospectus on August 6, 2026, increasing the shares available for sale under an Open Market Sale Agreement (ATM offering) with Jefferies LLC by an additional $500 million, following prior $550 million in sales.","company_name":"CG Oncology, Inc.","ticker":"CGON","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26444,"accession_number":"0001193125-26-336886","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 8.01 disclosure centers on Amendment No. 2 to the prospectus filed August 6, 2026, which increases the shares available for sale under an Open Market Sale Agreement (ATM offering) by an additional $500 million. This is a material dilutive equity issuance under an existing ATM facility with Jefferies LLC, following a prior $550 million in sales. The supplemental earnings release (EX-99.1) is secondary context; the primary 8-K event is the prospectus amendment authorizing additional equity sales.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:56:15.688702+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26443,"accession_number":"0001193125-26-336886","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"CG Oncology issued a press release on August 6, 2026 announcing financial results for the quarter ended June 30, 2026, including condensed consolidated statements of operations and balance sheet data. The filing explicitly states \"CG Oncology Reports Second Quarter 2026 Financial Results\" and discloses key metrics such as net loss of $79.1 million (vs. $41.4 million prior year), R\u0026D expenses of $54.7 million, and cash position of $1.0 billion. This is a standard quarterly earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:56:15.688702+00:00","company_name":"CG Oncology, Inc.","ticker":"CGON","filing_date":"2026-08-06"},{"id":26444,"accession_number":"0001193125-26-336886","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 8.01 disclosure centers on Amendment No. 2 to the prospectus filed August 6, 2026, which increases the shares available for sale under an Open Market Sale Agreement (ATM offering) by an additional $500 million. This is a material dilutive equity issuance under an existing ATM facility with Jefferies LLC, following a prior $550 million in sales. The supplemental earnings release (EX-99.1) is secondary context; the primary 8-K event is the prospectus amendment authorizing additional equity sales.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:56:15.688702+00:00","company_name":"CG Oncology, Inc.","ticker":"CGON","filing_date":"2026-08-06"}]}